Tuberculosis remains one of the most consequential infectious diseases in human history, yet its true global toll — stratified by HIV co-infection, drug resistance, age, and sex — has rarely been captured at this scale. As international health funding contracts and WHO's 2035 End TB targets grow increasingly uncertain, understanding the pre-disruption baseline becomes critical for preserving decades of hard-won progress.
This landmark systematic analysis from the Global Burden of Disease (GBD) 2023 consortium quantifies TB mortality, morbidity, and disability-adjusted life-years (DALYs) across 204 countries and territories spanning 1990 to 2023. Using the Cause of Death Ensemble model alongside DisMod-MR 2.1, researchers simultaneously modeled incidence, prevalence, and mortality by age and sex, then stratified estimates by HIV status and multidrug resistance using a population attributable fraction framework. Risk factor contributions — specifically alcohol use, smoking, and elevated fasting plasma glucose — were disaggregated through comparative risk assessment, offering a more mechanistic view of modifiable TB vulnerability than prior GBD iterations.
The analytical scope here represents a meaningful methodological advance over earlier TB burden assessments. By integrating vital registration, verbal autopsy, surveillance, and minimally invasive tissue sampling data, the study addresses a longstanding challenge: TB deaths are chronically underreported in the high-burden settings where they concentrate. The HIV-TB co-infection stratification is particularly valuable, since HIV-positive individuals face dramatically elevated TB mortality risk and respond differently to standard treatment protocols. The inclusion of MDR-TB as a separate burden category reflects the escalating threat of drug-resistant strains, which now account for a disproportionate share of treatment failures globally. For health-conscious adults tracking infectious disease risk, the modifiable risk factor findings — linking alcohol, smoking, and metabolic dysregulation to TB susceptibility — offer a rare, population-level lens on individual behaviors that intersect with pandemic-scale disease. Methodologically, this is a confirmatory and expansive study rather than a paradigm-shifting one, but its scope and timing make it an essential policy reference.